Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Sep 2;3(9):e189. doi: 10.1038/mtna.2014.35

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014 American Society of Gene & Cell Therapy

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

PMC Copyright notice

RPN2 regulates malignant phenotypes of osteosarcoma cells. (a) The relative expression levels of RPN2 mRNA in osteosarcoma cell lines. Data are presented as mean ± SD (n = 3 per group). N.S., not significant, *P < 0.05; Student's t-test. (b) Knockdown of RPN2 mRNA by shRNA, as confirmed using real-time RT-PCR. Data are presented as mean ± SD (n = 3 per group). *P < 0.05; Student's t-test. (c) Western blot analysis of RPN2 protein in 143B-shRPN2 and 143B-shNC cells. (d) Relative proliferation rates of 143B-shRPN2 and 143B-shNC cells on day 3. Data are presented as mean ± SD (n = 3 per group). *P < 0.05; Student's t-test. (e) Phase-contrast micrograph of 143B-shRPN2 and 143B-shNC cells in the presence of 400 nmol/l doxorubicin (DOX). Scale bar, 200 μm. (f) Drug sensitivity of 143B-shRPN2 and 143B-shNC cells in the presence of doxorubicin (DOX), cisplatin (CDDP), methotrexate (MTX), and docetaxel (DOC). Data are presented as mean ± SD (n = 6 per group). N.S., not significant, **P < 0.01, ***P < 0.001; Student's t-test. (g) Phase-contrast micrograph of the 143B-shRPN2 and 143B-shNC cells in a serum-free, growth factor-supplemented, anchorage-independent environment. Scale bar, 100 μm. (h) Relative sphere formation efficacy of 143B-shRPN2 and 143B-shNC cells observed in g. Spheroids with a diameter beyond 100 μm were counted. Data are presented as mean ± SD (n = 3 per group). **P < 0.01; Student's t-test. (i) Phase-contrast micrograph of the invaded cells of 143B-shRPN2 and 143B-shNC cells. (j) Relative invasiveness of 143B-shRPN2 and 143B-shNC cells observed in i. Data are presented as mean ± SD (n = 3 per group). **P < 0.01; Student's t-test.